Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7513265 | 0.84 | KDM4E (0.59) | ALDH1A1KMT2AMEN1KDM4ECYP3A4 | |
| SCHEMBL15682719 | 0.83 | MAPT (0.63) | ALDH1A1KMT2AMEN1MAPTCYP2C9 | |
| SCHEMBL11437459 | 0.80 | KMT2A (0.64) | ALDH1A1KMT2AMEN1KDM4EMAPT | |
| SCHEMBL2090421 | 0.78 | ATM (0.58) | ALDH1A1KMT2AMEN1MAPTCYP3A4 | |
| SCHEMBL20704761 | 0.78 | DHODH (0.58) | ALDH1A1KMT2AMEN1KDM4EMAPT | |
| SCHEMBL11398329 | 0.78 | MAPT (0.56) | ALDH1A1KMT2AMEN1KDM4EMAPT | |
| SCHEMBL7505473 | 0.77 | ALDH1A1 (0.70) | ALDH1A1KMT2AMEN1KDM4EMAPT | |
| SCHEMBL11287711 | 0.77 | KDM4E (0.51) | ALDH1A1KMT2AMEN1KDM4EMAPT | |
| SCHEMBL11408843 | 0.76 | MAPT (0.83) | ALDH1A1KDM4EMAPTCYP19A1GAA | |
| SCHEMBL29663729 | 0.76 | MAPT (0.69) | ALDH1A1KMT2AMEN1MAPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546397-B2 | DNA methylation inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120157465-A1 | DNA METHYLATION INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-06-21 | — | — | US | disclosed |
| US-4191840-A | Oxamic acid derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1980-03-04 | — | — | US | disclosed |
| US-4160100-A | OXAMIC ACID DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1979-07-03 | — | — | US | disclosed |
| US-4154961-A | Oxamic acid derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1979-05-15 | — | — | US | disclosed |
| US-4069343-A | OXAMIC ACID DERIVATIVES FOR THE PREVENTION OF IMMEDIATE TYPE HYPERSENSITIVITY REACTIONS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-01-17 | — | — | US | disclosed |
| US-4054661-A | Pyridyl oxamic acid derivatives and use in the prevention of allergic reactions | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-10-18 | — | — | US | disclosed |
| US-4054657-A | Pyrimidinyl oxamic acids and esters, and compositions and methods for the suppression of allergic manifestations | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-10-18 | — | — | US | disclosed |
| US-4054666-A | Compositions and methods of treating immediate hypersensitivity reactions with thiazolyl oxamic acid derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-10-18 | — | — | US | disclosed |
| US-4036837-A | 2 Alkoxyoxamoyl-pyrazines | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-07-19 | — | — | US | disclosed |
| US-3966965-A | Oxamic acid derivatives for the prevention of immediate type hypersensitivity reactions | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157465-A1 | DNA METHYLATION INHIBITORS | MECP2, DNMT1, DNMT3B | ALDH1A1 2789/4885KMT2A 17/4885MEN1 3018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.